FDA Approves Indication Expansion For Heron Therapeutics' Post-Op Pain Med

The FDA has approved Heron Therapeutics Inc's HRTX supplemental application for Zynrelef (bupivacaine and meloxicam) extended-release solution to expand the indication. 

  • Zynrelef is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
  • Zynrelef demonstrated superior, sustained postoperative pain relief for up to 72 hours and decreased the need for opioids, with more patients opioid-free compared to bupivacaine solution.
  • This expanded indication for Zynrelef will now cover approximately 7 million procedures annually. 
  • Heron plans to submit a second supplemental application to the FDA in 2H of 2022 to support a broad indication for soft tissue and orthopedic surgical procedures, intended to cover the full 14 million target procedures.
  • Price Action: HRTX shares are up 16.10% at $9.69 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!